cabergoline has been researched along with Lipodystrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bredella, MA; Dichtel, LE; Gerweck, AV; Miller, KK; Schorr, M; Swearingen, B; Woodmansee, WW; Young, BJ | 1 |
| Aller, J; Alvarez-Escolá, C; Bernabeu, I; Biagetti, B; Blanco, C; Cámara, R; Castells, I; Fajardo, C; García, R; Gaztambide, S; Mora, M; Picó, A; Pozo, CD; Resmini, E; Salinas, I; Sesmilo, G; Soto, A; Torres, E; Villabona, C; Webb, SM | 1 |
2 other study(ies) available for cabergoline and Lipodystrophy
| Article | Year |
|---|---|
Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.
Topics: Acromegaly; Adipose Tissue; Adult; Aged; Blood Glucose; Body Composition; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Ergolines; Female; Gonadal Steroid Hormones; Human Growth Hormone; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Lipid Metabolism Disorders; Lipodystrophy; Male; Middle Aged; Peptides, Cyclic; Prednisone; Somatostatin | 2017 |
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.
Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Injections, Subcutaneous; Insulin-Like Growth Factor I; Lipodystrophy; Male; Middle Aged; Octreotide; Receptors, Somatotropin; Retrospective Studies; Spain; Treatment Failure; Treatment Outcome | 2014 |